These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 21751945)

  • 1. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.
    Silverstein SM; Cable MG; Sadri E; Peace JH; Fong R; Chandler SP; Gow JA; Klier SM; McNamara TR;
    Curr Med Res Opin; 2011 Sep; 27(9):1693-703. PubMed ID: 21751945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.
    Henderson BA; Gayton JL; Chandler SP; Gow JA; Klier SM; McNamara TR;
    Ophthalmology; 2011 Nov; 118(11):2120-7. PubMed ID: 21762992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
    Donnenfeld ED; Holland EJ; Stewart RH; Gow JA; Grillone LR;
    Ophthalmology; 2007 Sep; 114(9):1653-62. PubMed ID: 17445902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials.
    Walters TR; Goldberg DF; Peace JH; Gow JA;
    Ophthalmology; 2014 Jan; 121(1):25-33. PubMed ID: 24021896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The systemic safety of bromfenac ophthalmic solution 0.09%.
    Stewart RH; Grillone LR; Shiffman ML; Donnenfeld ED; Gow JA;
    J Ocul Pharmacol Ther; 2007 Dec; 23(6):601-12. PubMed ID: 18001250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery.
    Miyanaga M; Miyai T; Nejima R; Maruyama Y; Miyata K; Kato S
    Acta Ophthalmol; 2009 May; 87(3):300-5. PubMed ID: 19183412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent.
    Jones J; Francis P
    Expert Opin Pharmacother; 2009 Oct; 10(14):2379-85. PubMed ID: 19735215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
    Bucci FA; Waterbury LD
    Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromfenac Ophthalmic Solution 0.07%: A Review of Its Use After Cataract Surgery.
    Hoy SM
    Clin Drug Investig; 2015 Aug; 35(8):525-9. PubMed ID: 26177719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery.
    Maxwell WA; Reiser HJ; Stewart RH; Cavanagh HD; Walters TR; Sager DP; Meuse PA
    J Ocul Pharmacol Ther; 2008 Dec; 24(6):593-9. PubMed ID: 19040348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of topically applied flurbiprofen or bromfenac ophthalmic solution on post-operative ocular hypertension in canine patients following cataract surgery.
    Lu J; English R; Nadelstein B; Weigt A; Berdoulay A; Binder D; Ngan E
    Vet Ophthalmol; 2017 Mar; 20(2):107-113. PubMed ID: 26990912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels.
    Bucci FA; Waterbury LD
    J Cataract Refract Surg; 2008 Sep; 34(9):1509-12. PubMed ID: 18721711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 2 regimens of loteprednol etabonate and bromfenac for cataract surgery.
    Al-Awadi A; Tokko HA; Chan CC; Somani S
    Can J Ophthalmol; 2019 Jun; 54(3):388-394. PubMed ID: 31109481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Comparative Efficacy and Tolerability of Diclofenac 0.1% and Bromfenac 0.09% Ophthalmic Solutions after Cataract Surgery.
    Giannaccare G; Finzi A; Sebastiani S; Greco F; Versura P; Campos EC
    Curr Eye Res; 2018 Dec; 43(12):1445-1453. PubMed ID: 30009640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the analgesic efficacy and safety of nepafenac ophthalmic suspension compared with diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase II, randomized, double-masked trial.
    Colin J; Paquette B
    Clin Ther; 2006 Apr; 28(4):527-36. PubMed ID: 16750464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery.
    Lane SS; Modi SS; Lehmann RP; Holland EJ
    J Cataract Refract Surg; 2007 Jan; 33(1):53-8. PubMed ID: 17189793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute corneal melt associated with topical bromfenac use.
    Prasher P
    Eye Contact Lens; 2012 Jul; 38(4):260-2. PubMed ID: 22169877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery.
    Silverstein SM; Jackson MA; Goldberg DF; Muñoz M
    Clin Ophthalmol; 2014; 8():965-72. PubMed ID: 24876763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of bromfenac for the treatment of corneal ulcer pain.
    Schechter BA; Trattler W
    Adv Ther; 2010 Oct; 27(10):756-61. PubMed ID: 20845001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.